Summary
Global Markets Direct’s, ‘Aurigene Discovery Technologies Limited - Product Pipeline Review - 2016’, provides an overview of the Aurigene Discovery Technologies Limited’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Aurigene Discovery Technologies Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Aurigene Discovery Technologies Limited
- The report provides overview of Aurigene Discovery Technologies Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Aurigene Discovery Technologies Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Aurigene Discovery Technologies Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Aurigene Discovery Technologies Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Aurigene Discovery Technologies Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aurigene Discovery Technologies Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Aurigene Discovery Technologies Limited Snapshot 6
Aurigene Discovery Technologies Limited Overview 6
Key Information 6
Key Facts 6
Aurigene Discovery Technologies Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Aurigene Discovery Technologies Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Aurigene Discovery Technologies Limited - Pipeline Products Glance 16
Aurigene Discovery Technologies Limited - Early Stage Pipeline Products 16
IND/CTA Filed Products/Combination Treatment Modalities 16
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Aurigene Discovery Technologies Limited - Drug Profiles 19
AUR-012 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Drugs to Target Fab Pathway for Gram Negative Bacterial Infections 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
AEA-16 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
AU-1702014 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
AU-4869 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CA-170 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CA-4948 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Drugs for Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Drugs to Inhibit EZH2 for Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Antagonize TIM-3 and PDL-1 for Oncology 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AU-2439 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drugs to Inhibit CDK9 and BET for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drugs to Inhibit MALT-1 for Oncology and Inflammation 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drugs to Inhibit TDO and IDO for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule to Inhibit CDK7 for Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Inhibit K-RAS for Oncology 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Aurigene Discovery Technologies Limited - Pipeline Analysis 37
Aurigene Discovery Technologies Limited - Pipeline Products by Target 37
Aurigene Discovery Technologies Limited - Pipeline Products by Route of Administration 39
Aurigene Discovery Technologies Limited - Pipeline Products by Molecule Type 40
Aurigene Discovery Technologies Limited - Pipeline Products by Mechanism of Action 41
Aurigene Discovery Technologies Limited - Recent Pipeline Updates 43
Aurigene Discovery Technologies Limited - Dormant Projects 45
Aurigene Discovery Technologies Limited - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Aurigene Discovery Technologies Limited, Key Information 6
Aurigene Discovery Technologies Limited, Key Facts 6
Aurigene Discovery Technologies Limited - Pipeline by Indication, 2016 8
Aurigene Discovery Technologies Limited - Pipeline by Stage of Development, 2016 10
Aurigene Discovery Technologies Limited - Monotherapy Products in Pipeline, 2016 11
Aurigene Discovery Technologies Limited - Partnered Products in Pipeline, 2016 12
Aurigene Discovery Technologies Limited - Partnered Products/ Combination Treatment Modalities, 2016 13
Aurigene Discovery Technologies Limited - Out-Licensed Products in Pipeline, 2016 14
Aurigene Discovery Technologies Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
Aurigene Discovery Technologies Limited - IND/CTA Filed, 2016 16
Aurigene Discovery Technologies Limited - Preclinical, 2016 17
Aurigene Discovery Technologies Limited - Discovery, 2016 18
Aurigene Discovery Technologies Limited - Pipeline by Target, 2016 38
Aurigene Discovery Technologies Limited - Pipeline by Route of Administration, 2016 39
Aurigene Discovery Technologies Limited - Pipeline by Molecule Type, 2016 40
Aurigene Discovery Technologies Limited - Pipeline Products by Mechanism of Action, 2016 42
Aurigene Discovery Technologies Limited - Recent Pipeline Updates, 2016 43
Aurigene Discovery Technologies Limited - Dormant Developmental Projects,2016 45
Aurigene Discovery Technologies Limited, Other Locations 46
Aurigene Discovery Technologies Limited, Subsidiaries 46
List of Figures
Aurigene Discovery Technologies Limited - Pipeline by Top 10 Indication, 2016 8
Aurigene Discovery Technologies Limited - Pipeline by Stage of Development, 2016 10
Aurigene Discovery Technologies Limited - Monotherapy Products in Pipeline, 2016 11
Aurigene Discovery Technologies Limited - Pipeline by Top 10 Target, 2016 37
Aurigene Discovery Technologies Limited - Pipeline by Molecule Type, 2016 40
Aurigene Discovery Technologies Limited - Pipeline Products by Top 10 Mechanism of Action, 2016 41
